文献速递艾滋病与性传播感染

布地格利单抗在HIV-1感染者中的安全性、药代与药效学

Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.
PubMed 文献 · J Infect Dis · 2026-01-01

这项随机安慰剂对照1b期研究评估了低剂量抗PD-1单抗布地格利单抗在病毒载量抑制的HIV感染者中的安全性、药代动力学和药效学。32名受试者接受单次10mg皮下、20mg皮下、10mg静脉或安慰剂,随访24周。结果显示安全性可接受,20mg皮下和10mg静脉的药代特征有利。

要点

  • 单次布地格利单抗总体安全,无≥4级不良事件或治疗相关严重不良事件。
  • 20mg皮下和10mg静脉给药后PD-1受体饱和度≥95%持续时间较长。
  • 20mg皮下暴露量超过剂量比例且变异较小,皮下生物利用度约53%-62%。

核心结论

  • 单次布地格利单抗在HIV感染者中安全性可接受,20mg皮下和10mg静脉药代特征有利。

研究设计与样本

  • 随机安慰剂对照1b期研究,每组8人接受单次10mg皮下、20mg皮下、10mg静脉或安慰剂,随访24周。

主要发现

  • 32名随机受试者中22人报告不良事件,多数为≤2级,无≥4级或治疗相关严重不良事件。
  • 报告2例非治疗相关3级不良事件:安慰剂组1例肺炎,10mg静脉组1例天冬氨酸氨基转移酶升高。
  • 报告1例可逆免疫相关不良事件(2级苔藓样角化病,20mg皮下组)。
  • 几何平均最大血清浓度:10mg皮下0.37µg/mL,20mg皮下1.57µg/mL,10mg静脉3.2µg/mL。
  • 20mg皮下较10mg皮下暴露量超过剂量比例且变异较小;皮下生物利用度约53%-62%。

关键数值与推荐

  • PD-1受体饱和度≥95%的中位持续时间:20mg皮下42天,10mg皮下14天,10mg静脉35天。

临床怎么用

  • 研究支持进一步评估布地格利单抗作为HIV治疗潜在组分,20mg皮下和10mg静脉值得关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blockade of inhibitory immune checkpoint receptor programmed cell death protein 1 (PD-1) on target immune cells is associated with improved HIV-specific immune function and activation of latent HIV. This randomized, placebo-controlled, Phase 1b study assessed low doses of investigational anti-PD-1 monoclonal antibody, budigalimab, for safety, tolerability, pharmacokinetics, and pharmacodynamics in people with HIV (PWH) on antiretroviral therapy. METHODS: Participants received single doses of budigalimab 10 mg subcutaneous (SC), 20 mg SC, 10 mg intravenous (IV), or placebo (n = 8 per arm) and were followed for 24 weeks. RESULTS: Of 32 randomized participants, 22 reported adverse event(s) (AE); most (n = 19) were grade ≤2 and no grade ≥4 AE or treatment-related serious AE. Two participants reported a non-treatment-related grade 3 AE (placebo, n = 1 pneumonia; 10 mg IV, n = 1 elevated aspartate aminotransferase). One reversible immune-related AE (grade 2 lichenoid keratosis) was reported (20 mg SC). Geometric mean maximum serum concentrations were 0.37, 1.57, and 3.2 µg/mL with 10 mg SC, 20 mg SC, and 10 mg IV, respectively. Drug exposure with 20 versus 10 mg SC dosing was more than dose proportional and less variable. Subcutaneous bioavailability was approximately 53%-62%. The PD-1 receptor saturation was ≥95% in most participants (median duration: 20 mg SC, 42 days; 10 mg SC, 14 days; 10 mg IV, 35 days). CONCLUSIONS: Findings suggest an acceptable safety profile for single-dose budigalimab in PWH, with a favorable pharmacokinetic profile for 20 mg SC and 10 mg IV. Further evaluation as a potential component of an HIV treatment is underway.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Vaidya TR, Geib T, Lalezari JP, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load. J Infect Dis. 2026. PMID: 41955081. doi:10.1093/infdis/jiag142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。